Combination therapy with lenalidomide and nanoceria ameliorates CNS autoimmunity

Area of Science:

• Neuroscience
• Immunology
• Nanomedicine

Background:

• Multiple sclerosis (MS) is a CNS autoimmune disorder causing demyelination and axonal damage.
• Inflammation and oxidative stress are key contributors to MS pathogenesis.
• Current MS treatments have limitations, necessitating novel therapeutic strategies.

Purpose of the Study:

• To evaluate the therapeutic efficacy of lenalidomide and cerium oxide nanoparticles (nanoceria) in the experimental autoimmune encephalomyelitis (EAE) mouse model of MS.
• To investigate the combined effects of lenalidomide and nanoceria on MS-like pathology and clinical symptoms.

Main Methods:

• EAE was induced in C57BL/6 mice, which were then treated with vehicle, lenalidomide, nanoceria, or a combination.
• Clinical EAE scores were monitored daily.
• MRI scans and histological/biochemical analyses assessed white matter pathology, demyelination, and inflammation.

Main Results:

• Lenalidomide alone delayed symptom onset; nanoceria alone promoted recovery.
• Both lenalidomide and nanoceria attenuated white matter pathology and inflammation.
• Combined treatment nearly eliminated EAE symptoms and significantly reduced pathology and inflammation compared to monotherapy.

Conclusions:

• Combined lenalidomide and nanoceria treatment effectively suppresses inflammation and oxidative stress in the EAE model.
• This combination therapy demonstrates significant preclinical efficacy in reducing demyelination and neurological symptoms.
• The findings suggest a potential therapeutic application for lenalidomide and nanoceria in treating multiple sclerosis.